Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. tumor detection
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • Older

Tumor Detection Articles & Analysis

18 news found

Tempus Announces the Clinical Launch of its MRD Testing Portfolio

Tempus Announces the Clinical Launch of its MRD Testing Portfolio

Tempus, a leader in artificial intelligence and precision medicine, today announced the clinical launch of its minimal residual disease (MRD) test portfolio, including Tempus’ xM test and the xM (NeXT Personal® Dx) test by Personalis. The portfolio features both a tumor-naïve assay and a tumor-informed assay that are designed to help ...

ByTempus


Circulating Tumor Cell detection by Menarini Group’s CELLSEARCH System leading to genomic profiling of myeloma cells shows potential for non-invasive management of Multiple Myeloma patients at early stages of disease

Circulating Tumor Cell detection by Menarini Group’s CELLSEARCH System leading to genomic profiling of myeloma cells shows potential for non-invasive management of Multiple Myeloma patients at early stages of disease

The majority of precursor patients analyzed in the study showed evidence of CTCs, with one or more CTCs detected in 82% of the overall enrolled population-. In addition, the data showed an increase in the number of CTCs from MGUS to SMM, confirming the correlation between a higher disease burden and greater trafficking of CTCs. ...

ByThe Menarini Group


CD Genomics Expands Its Sequencing Portfolio with the Launch of Whole Exome Sequencing

CD Genomics Expands Its Sequencing Portfolio with the Launch of Whole Exome Sequencing

Cancer Mutations within the entire exon region of cancerous genomes are more likely to induce tumor development. Accurate detection of SNV and InDel through whole exome sequencing can efficiently analyze cancer susceptibility and disease-causing genes, providing a reliable method for cancer genome research. ...

ByCD Genomics


Cirdan, Queen’s University Belfast and KTP Associate Jonathan Armstrong win Innovate UK’s award for Best KTP 2022

Cirdan, Queen’s University Belfast and KTP Associate Jonathan Armstrong win Innovate UK’s award for Best KTP 2022

Cirdan are delighted to announce that together with Queen’s University Belfast and our KTP Associate and Senior AI Engineer, Jonathan Armstrong, we have been selected as the winners of the Best KTP project by Innovate UK. Innovate UK’s Best Knowledge Transfer Partnership award honours the KTP which has brought the greatest benefits to all three participants, exceeding the expectations ...

ByCirdan Ltd


Cirdan, Queen’s University Belfast and KTP Associate Jonathan Armstrong shortlisted for Innovate UK’s Best Knowledge Transfer Partnership Award

Cirdan, Queen’s University Belfast and KTP Associate Jonathan Armstrong shortlisted for Innovate UK’s Best Knowledge Transfer Partnership Award

Cirdan are delighted to announce that together with Queen’s University Belfast and our KTP Associate and Senior AI Engineer, Jonathan Armstrong, we have been shortlisted for Innovate UK’s esteemed Best Knowledge Transfer Partnership Award. Innovate UK’s Best Knowledge Transfer Partnership award honours the KTP which has brought the greatest benefits to all three participants, ...

ByCirdan Ltd


Cancer Treatment is the USA: Methods, Top Clinics, Cost, Financing Options

Cancer Treatment is the USA: Methods, Top Clinics, Cost, Financing Options

The USA boasts better cancer survival rates than most other developed countries. This was made possible due to a number of factors. In America, much attention is paid to medical equipment. Local oncology centers are equipped with the latest technology, actively use innovative technologies and new medicines. In addition, oncology in the United States involves extensive screening and more ...

ByProUroCare Medical Inc.


Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedical’s Proprietary Suprachoroidal Space Platform

Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedical’s Proprietary Suprachoroidal Space Platform

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that clinical data from multiple internal and partnered programs were presented at the recent 2022 Annual Meeting of the American Academy of Ophthalmology (AAO), the world's largest association of eye ...

ByClearside Biomedical


Creative Proteomics Cytokine Unveils Tumor Necrosis Factors (TNF) Detection Service

Creative Proteomics Cytokine Unveils Tumor Necrosis Factors (TNF) Detection Service

Creative Proteomics Cytokine recently announced the launch of the high-sensitivity Tumor Necrosis Factors (TNF) Detection Service to help with your TNF research. ...

ByCreative Proteomics


Made in Quebec: Illuminating hidden brain cancer cells

Made in Quebec: Illuminating hidden brain cancer cells

It’s a scene that plays out daily in operating rooms around the world: a surgeon removes a malignant brain tumour. But rather than registering the satisfaction of having saved a patient’s life, hanging in the air is an all-too-real statistic; in 99.5% of these operations, unseen cancer cells remain. That hidden cancer will eventually grow and spread, and the operation will have become ...

ByReveal Surgical


Avelas Makes Senior Appointments and Provides Update on Pegloprastide Phase III Clinical Program

Avelas Makes Senior Appointments and Provides Update on Pegloprastide Phase III Clinical Program

Ambareen Sheriff appointed as Vice President, Regulatory and Quality and Robin Stevens appointed as Non-Executive Director Novel, best-in-class agent for visualizing breast cancer margins to enter Phase III trial in 1H22 SAN DIEGO, CA – Avelas Biosciences, Inc. (“Avelas” or “the Company”), a clinical-stage drug-device company pioneering the field of fluorescence ...

ByAvelas Biosciences


Circulating atypical cells detected in blood of lung cancer patients

Circulating atypical cells detected in blood of lung cancer patients

New study data presented at the European Congress of Cytology – held from 3-6 Oct in Warsaw, Poland – confirmed that X-ZELL is able to detect tumour-associated circulating atypical cells in the blood of lung cancer patients The dataset comprised interim results from a pilot study carried out in Thailand by X-ZELL and Dr Kittipong Maneechotesuwan from Mahidol University’s ...

ByX-Zell Inc.


Preventive Cancer Vaccine Trial Releases Two-Year Safety Evaluation

Preventive Cancer Vaccine Trial Releases Two-Year Safety Evaluation

“For example, we are seeing a higher percentage of dogs with early-stage rather than late-stage tumors than observed in normal practice. We think this may be due in part to the regular, six-month exams the dogs ...

ByCalviri


ODS Medical, Inc. closes a new financing round to further support product development diversification of applications

ODS Medical, Inc. closes a new financing round to further support product development diversification of applications

These tools are bringing real time tissue characterization to operating rooms and diagnostic suites, detecting the presence of invasive cancer directly in the patient during procedures. ...

ByReveal Surgical


Nucleix Presents Clinical Data at EAU21 Virtual Congress Which Demonstrates Promising Advances in the Care of Bladder Cancer Patients

Nucleix Presents Clinical Data at EAU21 Virtual Congress Which Demonstrates Promising Advances in the Care of Bladder Cancer Patients

Due to Bladder EpiCheck’s high sensitivity for high-grade disease and high specificity, and a well-planned infrastructure, all high-grade tumors, including muscle invasive tumors, were detected while avoiding 76% of unnecessary cystoscopies,” said Fred Witjes, M.D., Professor of Medical Sciences at Radboud University Medical Center. ...

ByNucleix Ltd.


FONAR To Ring The Nasdaq Stock Market Closing Bell, As It Celebrates 50th Birthday of MRI

FONAR To Ring The Nasdaq Stock Market Closing Bell, As It Celebrates 50th Birthday of MRI

FONAR Corporation (NASDAQ-FONR), The Inventor of MR Scanning™, will ring the Nasdaq Stock Market Closing Bell on March 9, 2021. Nasdaq and FONAR selected this day as it is 50 years since the discovery of MRI by Raymond V. Damadian, M.D., FONAR’s founder and chairman, was published in the widely-read, peer-reviewed scientific journal Science on March 19, 1971.* To access the live ...

ByFonar Corporation


SurgiMab announces recruitment of first US patient in pivotal Phase 3 clinical trial evaluating SGM-101 in colorectal cancer patients

SurgiMab announces recruitment of first US patient in pivotal Phase 3 clinical trial evaluating SGM-101 in colorectal cancer patients

SGM-101 is being developed to provide cancer surgeons with a novel intraoperative imaging tool designed to improve the visualization of tumor tissues overexpressing CEA in real-time during surgery. The aim of the study is to demonstrate that SGM-101 could be used to enable surgeons to more clearly delineate the margin between tumor tissue and healthy tissue. If ...

BySurgiMab


SurgiMab advances SGM-101 into pivotal Phase 3 clinical trial to improve surgical outcomes in colorectal cancer patients

SurgiMab advances SGM-101 into pivotal Phase 3 clinical trial to improve surgical outcomes in colorectal cancer patients

SGM-101 is being developed to provide cancer surgeons with a novel intraoperative imaging tool that enables them to visualize tumor tissues overexpressing CEA in real-time during surgery. This allows surgeons to more clearly delineate the margin between tumor tissue and healthy tissue, enabling a more accurate and complete resection of tumor ...

BySurgiMab


SurgiMab and Quest Medical Imaging announce Collaboration Agreement for phase III Clinical Trial

SurgiMab and Quest Medical Imaging announce Collaboration Agreement for phase III Clinical Trial

Françoise Cailler, CEO of SurgiMab, said “We are looking forward to working with Quest for the pivotal trial of our lead compound SGM-101 Indeed, SGM-101’s cancer targeting properties give it the potential to facilitate the detection and visualization of malignant tissue when used during image guided surgery. Our hope is that this real-time visualization of ...

BySurgiMab

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT